Prosecution Insights
Last updated: November 08, 2026
Application No. 18/697,432

COMPOSITION FOR ALLEVIATING HAIR LOSS AND PROMOTING HAIR GROWTH COMPRISING OAT EXTRACT

Final Rejection §102§103
Filed
Mar 29, 2024
Priority
Oct 01, 2021 — RE 10-2021-0131114 +1 more
Examiner
MOREAU, NASHARA LOUISE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Republic Of Korea(Management : Rural Development Administration)
OA Round
2 (Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
-10%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
4 granted / 7 resolved
-2.9% vs TC avg
Minimal -67% lift
Without
With
+-66.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
63 currently pending
Career history
77
Total Applications
across all art units

Statute-Specific Performance

§101
19.8%
-20.2% vs TC avg
§103
33.5%
-6.5% vs TC avg
§102
17.1%
-22.9% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 7 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claim(s) 1-5 and Chemical Formula 2 for claim 4 as the elected species in the reply filed on April 08, 2026 is acknowledged. Claim(s) 14-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claim(s) 1-5 are examined on the merits. Information Disclosure Statement The information disclosure statements (IDSs) submitted on March 29, 2024 and April 30, 2024 are being considered by the examiner. The signed IDS forms are attached with the instant office action. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ueda (JP 2010143862 A – English translation provided) with Bahraminejad et al (Journal of Phytopathology, (Year: 2008), vol. 156, pp. 1-7), providing inherent characteristics of Ueda. Ueda teaches [that] the composition contain[s] an extract of one or more kinds of plants selected from green oat ([green oat is a synonym for Avena sativa, oat, oats, and common oat]) (abstract). Ueda teaches that the composition contains the extracts obtained by using a solvent selected from water, ethanol and water-ethanol mixture and is used as an external preparation for skin or an oral administration composition [and also teaches that the composition has] excellent hair-growing effect (abstract). Ueda teaches [that] the green oat extract used in the present invention is an extract of leaves, stems, seeds or aboveground parts of green oats, which is a gramineous plant native to the Eurasian continent, also called oats or oats (page 3). The Ueda reference does not explicitly state that the composition contains Chemical Formula 2 ([e.g. 26-desglucoavenacoside B]) as specifically claimed by the applicant in claim 4 of the present invention. However, Bahraminejad et al demonstrates that 26-desglucoavenacoside B is known to occur within the extract of shoots of oat (e.g. oat grass or leaves) (abstract and figure at the bottom of page 1). The Ueda reference does teach the benefit of consuming an extract of oat in terms of improving hair growth, in which, naturally, that would mean that the extract naturally contains the chemical formula 2 (e.g. 26-desglucoavenacoside B). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1 and 5 are rejected under 35 U.S.C. 103 as being unpatentable over Ueda (JP 2010143862 A – English translation provided) in view of Bahraminejad et al (Journal of Phytopathology, (Year: 2008), vol. 156, pp. 1-7) and Lange (CA 3092158 A1). The teachings of Ueda and Bahraminejad et al are above. Ueda does not teach the composition that further comprises any one or more selected from the group consisting of hyaluronic acid and collagen. Lange teaches that the composition of the present invention can comprise collagen and hyaluronic acid (paragraph 0088). Lange teaches mixtures comprising a protein extract for the treatment of human skin and/or hair (under ‘Description’, page 1). Lange teaches [that] the present invention belongs to the area of hair care products (paragraph 0001). Regarding claim 5, the composition as taught by Ueda can be modified to further include hyaluronic acid and/or collagen as taught by Lange in order to create the optimal hair care composition to stimulate hair growth or hair loss improvement. It is well known that it is prima facie obvious to combine two or more ingredients each of which is taught by the prior art to be useful for the same purpose in order to form a third composition which is useful for the same purpose. The idea for combining them flows logically from their having been used individually in the prior art. See MPEP section 2144.06, In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980), Ex parte Quadranti, 25 USPQ2d 1071 (Bd. Pat. App. & Inter. 1992). One of ordinary skill in the art would reasonably expect to combine all of the aforementioned references in order to achieve the present invention’s hair care composition. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nashara L Moreau whose telephone number is (571)272-5804. The examiner can normally be reached Monday - Thursday, 8 AM - 4 PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached at (571)272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. NASHARA L MOREAUExaminer, Art Unit 1655 /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Mar 29, 2024
Application Filed
May 18, 2026
Non-Final Rejection mailed — §102, §103
Aug 18, 2026
Response Filed
Nov 06, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12751987
METHODS FOR INHIBITING SKIN DAMAGE, REDUCING SKIN SAGGING, REDUCING SKIN PORPHYRIN CONTENT, OR INCREASING FERRITIN CONTENT BY USING QUEEN PLUM EXTRACT
2y 10m to grant Granted Oct 06, 2026
Patent 12728149
PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DEPRESSION, COMPRISING HERBAL MEDICINE COMPLEX EXTRACTS OF ZIZYPHI SPINOSI SEMEN, JUJUBAE FRUCTUS, HORDEI FRUCTUS GERMINATUS, GLYCYRRHIZAE RADIX ET RHIZOMA, ANGELICAE GIGANTIS RADIX, AND BETA VULGARIS AS ACTIVE INGREDIENTS
2y 8m to grant Granted Sep 08, 2026
Patent 12691152
MEDICINE FOR TOPICAL WOUND TREATMENT
2y 6m to grant Granted Jul 28, 2026
Patent 12544416
MANUFACTURING METHOD FOR COMPOSITION PROMOTING BONE DENSITY ENHANCEMENT
2y 1m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 4 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
-10%
With Interview (-66.7%)
2y 10m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 7 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month